N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.3 NOK 1.77% Market Closed
Market Cap: 751.1m NOK

Wall Street
Price Targets

NYKD Price Targets Summary
Nykode Therapeutics ASA

Wall Street analysts forecast NYKD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NYKD is 5.46 NOK with a low forecast of 2.22 NOK and a high forecast of 8.93 NOK.

Lowest
Price Target
2.22 NOK
3% Downside
Average
Price Target
5.46 NOK
137% Upside
Highest
Price Target
8.93 NOK
288% Upside
Nykode Therapeutics ASA Competitors:
Price Targets
ZNTL
Zentalis Pharmaceuticals Inc
287% Upside
006280
Green Cross Corp
21% Upside
SCLP
Scancell Holdings PLC
214% Upside
PRQR
ProQR Therapeutics NV
338% Upside
ALCLS
Cellectis SA
64% Upside
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
28% Upside
UTHR
United Therapeutics Corp
1% Upside

Revenue
Forecast

Revenue Estimate
Nykode Therapeutics ASA

For the last 7 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 110%. The projected CAGR for the next 3 years is -47%.

110%
Past Growth
-47%
Estimated Growth
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Nykode Therapeutics ASA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Nykode Therapeutics ASA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NYKD's stock price target?
Price Target
5.46 NOK

According to Wall Street analysts, the average 1-year price target for NYKD is 5.46 NOK with a low forecast of 2.22 NOK and a high forecast of 8.93 NOK.

What is Nykode Therapeutics ASA's Revenue forecast?
Projected CAGR
-47%

For the last 7 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 110%. The projected CAGR for the next 3 years is -47%.

Back to Top